Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids
Status:
Terminated
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
Premenopausal women with symptomatic uterine fibroids will be randomized to either Proellex
25mg or 50mg or placebo for one treatment cycle (four months). Safety and effectiveness
between 50 mg versus placebo, and between 25mg and placebo will be analyzed.